Valeant’s Higher Bid Seals The Deal With Salix, Ending Endo’s Quest
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant raised its offer to buy the GI specialist from $158 to $173 per share in cash; Salix’s board of directors accepted the revised offer, ending a bid by Endo to buy the company.